Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
KIS protects against adverse vascular remodeling by opposing stathmin-mediated VSMC migration in mice
Thomas H. Langenickel, … , Martin F. Crook, Elizabeth G. Nabel
Thomas H. Langenickel, … , Martin F. Crook, Elizabeth G. Nabel
Published November 13, 2008
Citation Information: J Clin Invest. 2008;118(12):3848-3859. https://doi.org/10.1172/JCI33206.
View: Text | PDF
Research Article Vascular biology

KIS protects against adverse vascular remodeling by opposing stathmin-mediated VSMC migration in mice

  • Text
  • PDF
Abstract

Vascular proliferative diseases are characterized by VSMC proliferation and migration. Kinase interacting with stathmin (KIS) targets 2 key regulators of cell proliferation and migration, the cyclin-dependent kinase inhibitor p27Kip1 and the microtubule-destabilizing protein stathmin. Phosphorylation of p27Kip1 by KIS leads to cell-cycle progression, whereas the target sequence and the physiological relevance of KIS-mediated stathmin phosphorylation in VSMCs are unknown. Here we demonstrated that vascular wound repair in KIS–/– mice resulted in accelerated formation of neointima, which is composed predominantly of VSMCs. Deletion of KIS increased VSMC migratory activity and cytoplasmic tubulin destabilizing activity, but abolished VSMC proliferation through the delayed nuclear export and degradation of p27Kip1. This promigratory phenotype resulted from increased stathmin protein levels, caused by a lack of KIS-mediated stathmin phosphorylation at serine 38 and diminished stathmin protein degradation. Downregulation of stathmin in KIS–/– VSMCs fully restored the phenotype, and stathmin-deficient mice demonstrated reduced lesion formation in response to vascular injury. These data suggest that KIS protects against excessive neointima formation by opposing stathmin-mediated VSMC migration and that VSMC migration represents a major mechanism of vascular wound repair, constituting a relevant target and mechanism for therapeutic interventions.

Authors

Thomas H. Langenickel, Michelle Olive, Manfred Boehm, Hong San, Martin F. Crook, Elizabeth G. Nabel

×

Figure 5

Delayed cell cycle progression in KIS–/– VSMCs.

Options: View larger image (or click on image) Download as PowerPoint
Delayed cell cycle progression in KIS–/– VSMCs.
   
(A and B) Western bl...
(A and B) Western blot of p27Kip1 using (A) total protein extracts of KIS+/+ and KIS–/– VSMCs after serum starvation (S) and 12 hours after cell cycle release (R), and (B) nuclear protein extract of KIS+/+ and KIS–/– VSMCs after serum starvation and 8 hours after cell cycle release. p27Kip1 was completely exported from the nucleus in KIS+/+ VSMCs, whereas KIS–/– VSMCs retained marked amounts of nuclear p27Kip1. GAPDH or LAP2 served as loading control. (C) KIS–/– VSMCs showed a delayed entry into the S-phase (BrdU incorporation). n = 4. (D) KIS–/– VSMCs proliferated slower than did KIS+/+ VSMCs. n = 9–15. (E) p27Kip1 localization in KIS+/+ and KIS–/– VSMCs after serum starvation and 8 hours after cell cycle release. After cell cycle release, most of the p27Kip1 located to the nucleus and cytoplasm of KIS–/– VSMCs, whereas most of the p27Kip1 was exported into the cytoplasm of KIS+/+ VSMCs. Rabbit IgG served as negative control. Scale bar: 20 μm. (F) Quantification of p27Kip1 immunostaining in the nucleus (nuc), cytoplasm (cyto), and nucleus and cytoplasm (nuc+cyto). n = 6. *P < 0.05, ***P < 0.001 vs. KIS+/+.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts